This is a single center, open label, single arm phase II clinical trial. The objective of this study is to assess the feasibility and efficacy of zanubrutinib combined with venetoclax and Rituximab in patients with previously untreated follicular lymphoma (FL) .
A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated
Stage II, III, or IV disease
Able and willing to provide written informed consent and to comply with the study protocol
at least one measurable disease
ECOG≤ 2
Absolute neutrophil count (ANC) > 1.0 x 10^9/L
Platelet count > 50 x 10^9/L
Prothrombin time (PT)/international normal ratio (INR) < 1.5 x (upper limit of normal) ULN and partial thromboplastin time (PTT) (activated partial thromboplastin time [aPTT]) < 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder). When treated with warfarin or other vitamin K antagonists, then INR ≤ 3.0)